Drug profile · INN
mogamulizumab-kpkc
POTELIGEO
mogamulizumab-kpkc (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — mogamulizumab-kpkc
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
mogamulizumab-kpkc (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
C-C chemokine receptor type 4 cross-linking agent
Primary target: C-C chemokine receptor type 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mogamulizumab-kpkc?
mogamulizumab-kpkc (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for mogamulizumab-kpkc?
POTELIGEO is a marketed brand name for mogamulizumab-kpkc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mogamulizumab-kpkc?
mogamulizumab-kpkc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.